Anavex Life Sciences Provides an Update on Rett Syndrome Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Anavex Life Sciences (AVXL) Slumps 38% After Study in Pediatric Rett Syndrome Fails
January 2, 2024 8:17 AM EST(Updated - January 2, 2024 8:21 AM EST)
Anavex Life Sciences (NASDAQ: AVXL) Slumps 38% After Study in Pediatric Rett Syndrome Fails
In an ad-hoc analysis, using the predefined mixed-effect model for repeated measure (MMRM) method, after 12 weeks of treatment, ANAVEX®2-73-treated patients... More